{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T04:15:37Z","timestamp":1761192937582,"version":"build-2065373602"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sonidegib is a novel treatment for locally advanced basal cell carcinoma (LaBCC) with demonstrated efficacy and safety in clinical trials. However, its real-world safety profile remains insufficiently characterized. This study aimed to evaluate the real-world safety of sonidegib by analyzing adverse event (AE) reports from the FDA Adverse Event Reporting System (FAERS), identifying both known and unexpected safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data for this study were obtained from the FAERS, covering the period from the third quarter of 2015 to the fourth quarter of 2024. Four disproportionality analysis methods were employed to detect positive signals associated with sonidegib, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). Additionally, time-to-onset (TTO) analysis of AEs was conducted, and sensitivity analyses were performed to assess the robustness of the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1,087 Individual Case Safety Reports (ICSRs) involving 2,496 adverse events were included. The analysis confirmed the occurrence of known AEs, such as muscle spasms and myalgia, while also identifying several unexpected AEs, including pneumonia, sepsis, urinary tract infection, and hyperkalemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study analyzed the real-world safety of sonidegib and emphasized the importance of continuous monitoring during the early stages of treatment. These findings provide important safety information for clinicians, but further research is needed to validate these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1642867","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T04:13:13Z","timestamp":1761192793000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world safety profile of sonidegib: a disproportionality analysis based on the FDA adverse event reporting system"],"prefix":"10.3389","volume":"15","author":[{"given":"Kaidi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengxiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiashu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.006","article-title":"Guidelines of care for the management of basal cell carcinoma","volume":"78","author":"Kim","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.060","article-title":"Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations","volume":"80","author":"Cameron","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113254","article-title":"European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023","volume":"192","author":"Peris","year":"2023","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216821","article-title":"Treatments on the horizon for locally advanced basal cell carcinoma","volume":"589","author":"Idriss","year":"2024","journal-title":"Cancer Lett"},{"key":"B5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1684\/ejd.2011.1633","article-title":"Genetic skin diseases predisposing to basal cell carcinoma","volume":"22","author":"Castori","year":"2012","journal-title":"Eur J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cells12212534","article-title":"Signaling pathways and therapeutic strategies in advanced basal cell carcinoma","volume":"12","author":"Vallini","year":"2023","journal-title":"Cells"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00763-x","article-title":"Efficacy and safety of sonic hedgehog inhibitors in basal cell carcinomas: an updated systematic review and meta-analysis (2009-2022)","volume":"24","author":"Nguyen","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)70100-2","article-title":"Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (Bolt): A multicentre, randomised, double-blind phase 2 trial","volume":"16","author":"Migden","year":"2015","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13098","article-title":"The value of patient reporting to the pharmacovigilance system: A systematic review","volume":"83","author":"In\u00e1cio","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2223952","article-title":"Post-marketing safety concerns with upadacitinib: A disproportionality analysis of the fda adverse event reporting system","volume":"22","author":"Wu","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-025-01896-1","article-title":"Real-world safety of deucravacitinib: insights from the food and drug administration adverse event reporting system","author":"Zhao","year":"2025","journal-title":"Int J Clin Pharm"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1458438","article-title":"Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of faers data","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18552","article-title":"Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase ii randomized, double-blind bolt study","volume":"182","author":"Dummer","year":"2020","journal-title":"Br J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jaad.2016.02.1226","article-title":"The 12-month analysis from basal cell carcinoma outcomes with lde225 treatment (Bolt): A phase ii, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma","volume":"75","author":"Dummer","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0186","article-title":"Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma","volume":"21","author":"Lacouture","year":"2016","journal-title":"Oncologist"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15531","article-title":"Sonidegib-induced muscle spasms in the treatment of basal cell carcinoma: strategies to adopt","volume":"35","author":"Villani","year":"2022","journal-title":"Dermatol Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.09.021","article-title":"Hedgehog partial agonism drives warburg-like metabolism in muscle and brown fat","volume":"151","author":"Teperino","year":"2012","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers8020022","article-title":"Targeting the sonic hedgehog signaling pathway: review of smoothened and gli inhibitors","volume":"8","author":"Rimkus","year":"2016","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2023.2259127","article-title":"The emerging role of the hedgehog signaling pathway in immunity response and autoimmune diseases","volume":"56","author":"Li","year":"2023","journal-title":"Autoimmunity"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.4.1869","article-title":"Sonic hedgehog promotes cell cycle progression in activated peripheral cd4(+) T lymphocytes","volume":"169","author":"Lowrey","year":"2002","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.10.5451","article-title":"Sonic hedgehog signaling modulates activation of and cytokine production by human peripheral cd4+ T cells","volume":"169","author":"Stewart","year":"2002","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2024.106518","article-title":"Hedgehog signalling in cd4(+) T helper cell polarisation","volume":"168","author":"Hanna","year":"2024","journal-title":"Int J Biochem Cell Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2024.03.030","article-title":"Kidney care in times of crises: A review","author":"Alasfar","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.92a.24067","article-title":"New atrial fibrillation guideline: modify risk, control rhythm, prevent progression","volume":"92","author":"Campbell","year":"2025","journal-title":"Cleve Clin J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/eurheartj\/ehae887","article-title":"Non-traditional risk factors for atrial fibrillation: epidemiology, mechanisms, and strategies","volume":"46","author":"Lu","year":"2025","journal-title":"Eur Heart J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2024.12.003","article-title":"Advancing personalised care in atrial fibrillation and stroke: the potential impact of ai from prevention to rehabilitation","volume":"35","author":"Ortega-Martorell","year":"2025","journal-title":"Trends Cardiovasc Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00588-8","article-title":"Key clinical adverse events in patients with advanced basal cell carcinoma treated with sonidegib or vismodegib: A post hoc analysis","volume":"11","author":"Gutzmer","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1186\/s12885-024-13101-z","article-title":"Interim analysis of the multinational, post-authorization safety study (Nisso) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma","volume":"24","author":"Gutzmer","year":"2024","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1642867\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T04:13:13Z","timestamp":1761192793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1642867\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":28,"alternative-id":["10.3389\/fonc.2025.1642867"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1642867","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"article-number":"1642867"}}